Deleted Tweets From Scott Gottlieb, R-D.C.

RT @RAPSorg: .@US_FDA Formally Recognizes First Public Genetic Database, @ClinGenResource | #Regulatory Focus… https://t.co/v8Dva3fXP6

The policy reflected in this guidance, when finalized, will make it easier for providers to use the same test in helping guide the use of a class of oncology therapeutic products, rather than one specific oncology therapeutic product within that class.

Today, #FDA released a draft guidance on companion diagnostics, which describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple drug or biological oncology products https://t.co/8xMLsjEJIb https://t.co/TEHcujiaTZ

#FDA continues to evaluate the safety of valsartan-containing products and will update the list of products included and not included in the recall as more information becomes available. Information for patients and healthcare providers can be found here: https://t.co/EXl8c3HEIU

RT @CDCFlu: During #NIVW we're spotlighting heroes who #fightflu. We call them #FluFighters. First, meet Lacey Eden, an assista… https://t.co/9uuTgKKFFw

We’re updating health care professionals and consumers of a voluntary recall for valsartan-containing products made by Mylan Pharmaceuticals due to the detection of an NDEA impurity. https://t.co/HZb3YT0060

Currently, specificity in labeling can limit a potentially broader use of a companion diagnostic that may be scientifically and clinically appropriate. We’re concerned that this situation isn’t optimal for patient care. This is among the reasons we’re advancing this new policy.

RT @Surgeon_General: It’s National Influenza Vaccination Week (#NIVW) which is a great time to get your #flushot if you haven’t already. Th… QT @Surgeon_General: I’m quite proud of my little #flufighter! So brave, and she’s doing her part to protect her community (especially h… https://t.co/Qxx9CQNSE7)

RT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA on the FDA’s new effort for developing and class labeling of in vitro… https://t.co/rVsdeF93WS

Congratulations to FDA’s @tmprowell for her continued thought leadership in advancing public health goals in oncology! QT @MedscapeOnc: Your top 5 #Oncologist Influencers at #SABCS18. Nice to see #WomeninMedicine represented. https://t.co/nj7XRE9zT8)

THREAD: We’re proud of the significant progress of #FDA’s orphan drug program.  We remain committed to the Modernization Plan and the recent GAO report will help shape out continued efforts to improve our orphan drug program, e.g. designation consistency. https://t.co/xgU1CSgapr

While we’ve had record approvals for rare disease products recently, there are still no treatments for most rare diseases https://t.co/LveOuHZAXR FDA is committed to improving the lives of patients with rare diseases and will take actions soon to advance the program and its goals

As noted in the HHS response, #FDA recently launched a new orphan drug designation review template to improve the process. We agree with GAO’s key recommendation on documenting and recording information in the background section of the template https://t.co/hDPVFu8tvx

We appreciate GAO’s acknowledgement that #FDA applies consistent criteria in evaluating requests for orphan drug designation and recognition of our achievements to improve the program. https://t.co/hDPVFu8tvx But there’s clearly more we can - and will - do.

RT @US_FDA: #FDAVoices looks at how FDA is working to help patients find effective new treatments and cures for illness, by adv… https://t.co/RDvBzKLSgA

We’re taking important new steps to address the safety and effectiveness of antiseptic hand washes and rubs used by food handlers – these products can be an important part of strategies for preventing foodborne diseases, more info: https://t.co/ab3IIcmeTu https://t.co/3O07zusL8E

RT @FDASpox: FLAGGING: Statement from @SGottliebFDA on how FDA’s draft guidance on companion diagnostic labeling & developing wi… https://t.co/tZ6Xfwg7Ka

RT @steveusdin1: FDA releases real-world evidence framework. Important note: RWE will be only for adding an indication to an approve… https://t.co/8f42cldX9h

The goal is to help vets better educate livestock producers and animal owners on the proper use of dewormers and ways to monitor and slow down the development of APR at the farm level: https://t.co/ECIzfCgQdy

THREAD: Antiparasitic resistance (APR) can be hazardous to grazing animals like horses, cattle, sheep and goats. #FDA is asking animal drug companies to change dewormer labels to inform vets, livestock producers and horse owners on ways to help slow the development of APR. https://t.co/SWfbkKQXhi

RT @RAPSorg: .@US_FDA Formally Recognizes First Public Genetic Database, @ClinGenResource | #Regulatory Focus… https://t.co/v8Dva3fXP6

The policy reflected in this guidance, when finalized, will make it easier for providers to use the same test in helping guide the use of a class of oncology therapeutic products, rather than one specific oncology therapeutic product within that class.

Today, #FDA released a draft guidance on companion diagnostics, which describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple drug or biological oncology products https://t.co/8xMLsjEJIb https://t.co/TEHcujiaTZ

#FDA continues to evaluate the safety of valsartan-containing products and will update the list of products included and not included in the recall as more information becomes available. Information for patients and healthcare providers can be found here: https://t.co/EXl8c3HEIU

RT @CDCFlu: During #NIVW we're spotlighting heroes who #fightflu. We call them #FluFighters. First, meet Lacey Eden, an assista… https://t.co/9uuTgKKFFw

We’re updating health care professionals and consumers of a voluntary recall for valsartan-containing products made by Mylan Pharmaceuticals due to the detection of an NDEA impurity. https://t.co/HZb3YT0060

Currently, specificity in labeling can limit a potentially broader use of a companion diagnostic that may be scientifically and clinically appropriate. We’re concerned that this situation isn’t optimal for patient care. This is among the reasons we’re advancing this new policy.

RT @Surgeon_General: It’s National Influenza Vaccination Week (#NIVW) which is a great time to get your #flushot if you haven’t already. Th… QT @Surgeon_General: I’m quite proud of my little #flufighter! So brave, and she’s doing her part to protect her community (especially h… https://t.co/Qxx9CQNSE7)

RT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA on the FDA’s new effort for developing and class labeling of in vitro… https://t.co/rVsdeF93WS

Congratulations to FDA’s @tmprowell for her continued thought leadership in advancing public health goals in oncology! QT @MedscapeOnc: Your top 5 #Oncologist Influencers at #SABCS18. Nice to see #WomeninMedicine represented. https://t.co/nj7XRE9zT8)

THREAD: We’re proud of the significant progress of #FDA’s orphan drug program.  We remain committed to the Modernization Plan and the recent GAO report will help shape out continued efforts to improve our orphan drug program, e.g. designation consistency. https://t.co/xgU1CSgapr

While we’ve had record approvals for rare disease products recently, there are still no treatments for most rare diseases https://t.co/LveOuHZAXR FDA is committed to improving the lives of patients with rare diseases and will take actions soon to advance the program and its goals

As noted in the HHS response, #FDA recently launched a new orphan drug designation review template to improve the process. We agree with GAO’s key recommendation on documenting and recording information in the background section of the template https://t.co/hDPVFu8tvx

We appreciate GAO’s acknowledgement that #FDA applies consistent criteria in evaluating requests for orphan drug designation and recognition of our achievements to improve the program. https://t.co/hDPVFu8tvx But there’s clearly more we can - and will - do.

RT @US_FDA: #FDAVoices looks at how FDA is working to help patients find effective new treatments and cures for illness, by adv… https://t.co/RDvBzKLSgA

We’re taking important new steps to address the safety and effectiveness of antiseptic hand washes and rubs used by food handlers – these products can be an important part of strategies for preventing foodborne diseases, more info: https://t.co/ab3IIcmeTu https://t.co/3O07zusL8E

RT @FDASpox: FLAGGING: Statement from @SGottliebFDA on how FDA’s draft guidance on companion diagnostic labeling & developing wi… https://t.co/tZ6Xfwg7Ka

RT @steveusdin1: FDA releases real-world evidence framework. Important note: RWE will be only for adding an indication to an approve… https://t.co/8f42cldX9h

The goal is to help vets better educate livestock producers and animal owners on the proper use of dewormers and ways to monitor and slow down the development of APR at the farm level: https://t.co/ECIzfCgQdy

THREAD: Antiparasitic resistance (APR) can be hazardous to grazing animals like horses, cattle, sheep and goats. #FDA is asking animal drug companies to change dewormer labels to inform vets, livestock producers and horse owners on ways to help slow the development of APR. https://t.co/SWfbkKQXhi